Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

AstraZeneca Q1 Profit Up 29%

April 29, 2010 6:16 am | News | Comments

Anglo-Swiss pharmaceutical company AstraZeneca PLC reported that first-quarter profit rose by 29 percent, but cautioned that comparisons will be tougher in the second half of the year when a key patent expires.


Integrated Response Technology

April 29, 2010 6:11 am | Product Releases | Comments

endpoint Clinical announced that PULSE, a fully configurable platform that allows users to design and deploy clinical trial Integrated Response Technology (IRT) systems, saves 40 percent on the development time of clinical trials.


TrialTrove Reaches Landmark 100k Trial

April 29, 2010 6:06 am | News | Comments

Citeline’s TrialTrove, a leading global pharmaceutical intelligence service, now tracks more than 100,000 clinical trials around the world, making it among the most comprehensive source of clinical trial information available.


Cardiac Safety Software

April 29, 2010 5:57 am | Product Releases | Comments

ERT, a leading provider of centralized services to the biopharmaceutical, medical device and related industries, announced the launch of Centralized Cardiac Safety 2.0, a portfolio of new solutions that enable a significant new approach to cardiac safety in clinical trials.


Trial Reporting

April 29, 2010 5:49 am | Product Releases | Comments

Almac Clinical Technologies announced the release of a new reporting solution for its IXRS integrated phone and web response technology, Almac Interactive Reporting.


Access Array System

April 28, 2010 6:29 am | Product Releases | Comments

Fluidigm Corporation released a protocol for the Access Array System that enables sequencing of amplicon libraries using GS FLX Titanium Series reagents on the 454 GS FLX sequencing system.


Sample Processor

April 28, 2010 6:24 am | Product Releases | Comments

Life Technologies Corporation debuted the life science industry’s first benchtop sample preparation system designed to increase productivity while eliminating manual and contamination-related challenges traditionally associated with protein and epigenetic protocols.


Debiopharm Begins Enrollment for Debio 0932

April 28, 2010 6:20 am | News | Comments

Debiopharm Group announced that it has started patient enrolment in its Phase 1 clinical trial for the small molecule inhibitor of heat shock protein 90 (Hsp90), Debio 0932.


Shire Receives Paragraph IV Notice for INTUNIV

April 28, 2010 6:16 am | News | Comments

Shire plc announces that it has received a Paragraph IV Notice Letter from Anchen Pharmaceuticals, Inc. advising of the filing of an abbreviated new drug application for a generic version of Shire’s INTUNIV.


Lucentis Improves Vision in Diabetic Macular Edema

April 28, 2010 6:10 am | News | Comments

Researchers have shown that ranibizumab (Lucentis) eye injections, often in combination with laser treatment, result in better vision than laser treatment alone for diabetes-associated swelling of the retina.


Researchers Find Possible Treatment for Bone Death

April 28, 2010 6:06 am | News | Comments

Researchers at Mount Sinai School of Medicine have found a potential new treatment for osteonecrosis, or the death of bone tissue, in people who are treated with steroids for several common medical conditions.


Phase Forward Profits Down 53%

April 28, 2010 6:02 am | News | Comments

Phase Forward Inc., a provider of data management software for drug safety and clinical trials, said its first-quarter profit fell 53 percent as business costs and operating expenses outstripped modest revenue gains.


Merck KGaA Profits Up Quarter Billion Dollars in Q1

April 28, 2010 5:58 am | News | Comments

The overall increase in profit came as revenues at the company, which also makes the cancer drug Erbitux and multiple sclerosis treatment Rebif, rose nearly 13 percent to nearly €2.1 billion in the January-March period compared with nearly €1.9 billion a year earlier.


Dirty Bomb Test May Help Cancer Researchers

April 28, 2010 5:52 am | by Lauran Neergaard | News | Comments

With a few drops of blood, scientists are creating a way to tell who's absorbed dangerous radiation levels, part of the government's preparations against a terrorist attack - and research that just might point toward new cancer care, too.


Novo Nordisk 1st Quarter Profits Rise 23%

April 28, 2010 5:47 am | News | Comments

Danish drug maker Novo Nordisk A/S said its first quarter profit soared 23 percent, helped by increased sales of its core insulin products.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.